LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-25 and is reviewed periodically as new material appears.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Isovaline is a rare amino acid found in the Murchison meteorite, which landed in Australia in 1969. The discovery of isovaline in the biosphere demonstrates an extraterrestrial origin of amino acids and has been linked to the homochirality of life on Earth, suggesting a role in the origin of life. Isovaline is an isomer of the common amino acid valine, with the position of one methyl group shifted slightly (from position 3 to position 2). The structure of isovaline is also somewhat similar to the amino acids GABA and glycine, the chief inhibitory neurotransmitters in the mammalian central nervous system. Isovaline acts as an analgesic in mice by activating peripheral GABAB receptors. In a mouse model of osteoarthritis isovaline restored mobility, suggesting inhibition of nociception by isovaline in the synovial membrane of the mouse knee. Isovaline does not cross the blood–brain barrier and does not enter into the brain or spinal cord. Isovaline acts downstream to the cyclooxygenase system that NSAIDs inhibit, suggesting a means to avoid adverse effects such as irritation of the gastrointestinal system.
=== Ultrastructure and electron microscopy === The 1970s and 1980s provided new insights into lichen structure at the subcellular level. Aino Henssen and Hans Jahns revolutionised morphology‑centred systematics in 1973 by publishing an anatomy‑driven classification that combined light microscopy and electron microscopy data on 68 characters spanning ascoma development (ontogeny), ascus structure and photobiont interfaces. Their tree anticipated several clades later corroborated by DNA—such as the segregation of Gomphillaceae and the heterogeneous nature of the Ostropales—and it cemented detailed developmental anatomy as an indispensable taxonomic tool. Transmission electron microscopy (TEM) let researchers view cell walls, membranes, and attachment sites where the fungal and algal partners meet. Rosmarie Honegger's 1986 TEM survey examined the fungus–alga interface in more than 40 lichens, all harbouring Trebouxia photobionts. She observed that lichen fungi form three main types of contact structures (called haustoria). In one type, the fungal filaments (hyphae) penetrate directly into the algal cell ("intracellular" haustoria). In another, the filaments push between layers of the algal cell wall without breaking the plasma membrane ("intraparietal"). In the third, the fungus simply presses against the algal cell wall ("wall-to-wall"). Each lichen lineage consistently uses only one of these interaction styles, making it a useful trait for classification.
As well as being extracted from nuclear waste, radioisotopes can be produced deliberately with nuclear reactors, exploiting the high flux of neutrons present. These neutrons activate elements placed within the reactor. A typical product from a nuclear reactor is iridium-192, from activation of iridium targets. The elements that have a large propensity to take up neutrons in the reactor are said to have a high neutron cross-section, but even at low cross-sections this process is generally economical. Particle accelerators such as cyclotrons accelerate particles to bombard a target to produce radionuclides. Cyclotrons accelerate (most often) protons at a target to produce positron-emitting radionuclides, e.g. fluorine-18. Radionuclide generators, standard for many medical isotopes, contain a parent radionuclide that decays to produce a shorter-lived radioactive daughter. A typical example is the technetium-99m generator, which employs molybdenum-99 produced in a reactor.
Sources: en.wikipedia.org
This caused another rapid expansion, particularly in Germany. Between 1877 and 1887, 130 German patents for azo dyes were filed and 105 new dyes made it to market. It also lead to a difference in how chemical companies interacted with consumers. German dye firms developed in-house marketing and distribution capabilities coordinated directly with their research and development departments. Paul Schützenberger, in response to what he had seen at the 1878 Universal Exposition commented, "The abundance, the variety of combinations is such that we do not know whether to be more amazed by their multiplicity or by the imagination required to name them. Indeed, it is by the thousands that dyers create, every season, new colors for their sample cards." Professional societies based on the synthetic dye industries began to form. By the First World War, the largest number of dyes sold in the market fell into the class of azo dyes. 1885, an azo-naphthol, Para-red, became the first water-insoluble organic pigment not containing acidic or basic groups.
== History == The practice originated within online incel and manosphere communities during the 2010s, where discussions attributed sexual success to the perceived genetic advantages held by certain men, calling them "Chads". The three main forums in which looksmaxxing originated from, concomitant with the black pill ideology, were the websites PUAHate.com, Sluthate.com, and Lookism.net (called the "PSL Forums", taken from their names). This overarching online community came to be known as the "PSL community". Along with their focus on looksmaxxing and black pill ideas, these websites also rejected mainstream dating culture and feminist perspectives. Looksmaxxing was framed as a strategy for social recognition. It especially involved the adaptation to the perceived dominant male beauty standards, as a means to attract women. These forums established their own measuring unit to rate looks, titled the PSL Scale (standing for "Perceived Sexual Levels", but also an abbreviation for each of the three main forums, in order). The PSL scale diverges from the traditional scale "x out of ten" numerical attractiveness rating system, in that it uses a rigorously hierarchical and systematic framework used to measure only facial attractiveness. It typically uses a scale from 1–8, and it was strictly designed with the aim of interpreting how women perceive men. Many of the terms and jargon associated with looksmaxxing find their origins on these forums.
The central nervous system (CNS), comprising the brain and spinal cord. Nerves that transmit signals from the CNS are called motor nerves. Nerves that exit from the brain are called cranial nerves while those exiting from the spinal cord are called spinal nerves. The peripheral nervous system (PNS), comprising mainly nerves, enclosed bundles of axons. The PNS is divided into: The somatic nervous system, which links the brain and spinal cord to sensory receptors and skeletal muscle. The autonomic nervous system, which is subdivided into: The sympathetic nervous system. The parasympathetic nervous system. The enteric nervous system, which controls the gastrointestinal system. The neurovascular unit comprises the cells and vasculature channels within the nervous system that regulate cerebral blood flow.
Sources: en.wikipedia.org
== Biography == Langevin received an MD degree from McGill University in 1978. She did a post doctoral research fellowship in Neurochemistry at the MRC Neurochemical Pharmacology Unit in Cambridge, England, a residency in Internal Medicine and a fellowship in Endocrinology and Metabolism at Johns Hopkins Hospital. She was a Professor in Residence of Medicine at Harvard Medical School, Brigham and Women's Hospital. She was also a part-time Professor of Neurology, Orthopedics and Rehabilitation at the University of Vermont College of Medicine. She was the Principal Investigator of two NIH-funded studies investigating the role of connective tissue in low back pain and the mechanisms of manual and movement based therapies. Her previous studies in humans and animal models have found that "needle grasp", the biomechanical component of de qi, may be caused by connective tissue winding around the needle. Helene Langevin was appointed as Director of the Osher Center for Integrative Medicine at Harvard Medical School and Brigham and Women's Hospital in November 2012.
Gene expression in mammals is regulated by many cis-regulatory elements, including core promoters and promoter-proximal elements that are located near the transcription start sites of genes, upstream on the DNA (towards the 5' region of the sense strand). Other important cis-regulatory modules are localized in DNA regions that are distant from the transcription start sites. These include enhancers, silencers, insulators and tethering elements. Enhancers and their associated transcription factors have a leading role in the regulation of gene expression. Enhancers are genome regions that regulate genes. Enhancers control cell-type-specific gene expression programs, most often by looping through long distances to come in physical proximity with the promoters of their target genes. Multiple enhancers, each often tens or hundred of thousands of nucleotides distant from their target genes, loop to their target gene promoters and coordinate with each other to control gene expression. The illustration shows an enhancer looping around to come into proximity with the promoter of a target gene. The loop is stabilized by a dimer of a connector protein (e.g. dimer of CTCF or YY1). One member of the dimer is anchored to its binding motif on the enhancer and the other member is anchored to its binding motif on the promoter (represented by the red zigzags in the illustration). Several cell function-specific transcription factors (among the about 1,600 transcription factors in a human cell) generally bind to specific motifs on an enhancer.
A glycome is the entire complement or complete set of all sugars, whether free or chemically bound in more complex molecules, of an organism. An alternative definition is the entirety of carbohydrates in a cell. The glycome may in fact be one of the most complex entities in nature. "Glycomics, analogous to genomics and proteomics, is the systematic study of all glycan structures of a given cell type or organism" and is a subset of glycobiology. "Carbohydrate", "glycan", "saccharide", and "sugar" are generic terms used interchangeably in this context and includes monosaccharides, oligosaccharides, polysaccharides, and derivatives of these compounds. Carbohydrates consist of "hydrated carbon", i.e. [CH2O]n. Monosaccharides are a carbohydrate that cannot be hydrolyzed into a simpler carbohydrate and are the building blocks of oligosaccharides and polysaccharides. Oligosaccharides are linear or branched chains of monosaccharides attached to one another via glycosidic linkages. The number of monosaccharide units can vary. Polysaccharides are glycans composed of repeating monosaccharides, generally greater than ten monosaccharide units in length. The glycome exceeds the complexity of the proteome as a result of the even greater diversity of the glycome's constituent carbohydrates and is further complicated by the sheer multiplicity of possibilities in the combination and interaction of the carbohydrates with each other and with proteins. "The spectrum of all glycan structures — the glycome — is immense.
Johnson, the Battlegroup commander; Commander John Stufflebeem, leader of the VFA-103 F-14 squadron; Lt Barry McKibben, of the tactical unit; the Northrop Grumman E-2 Hawkeye airborne early warning aircraft, with Lt Scotty Bruce, Tactical Coordination officer, who watched for unidentified 'bogies' - the E-2 could take control of the fighter aircraft for the best interception; the E-6A Prowler had electronic jamming and could launch the AGM-88 HARM missile; Lt Chris Heath, Prowler pilot and Lt Darryl Leinhardt, electronic countermeasures officer; the HOTAS and forward-looking infrared systems of the Hornet; Commander Richard Kurrus aircraft handling officer; on landing, pilots attempt to catch the third of four wires; the Harold Wilson government of the UK decided to retire the UK's large strike carriers in 1966, which may have prompted the Falklands War, as the Argentinians would not have contemplated such an invasion otherwise; the French have the largest Navy in Europe, with its Foch carrier, and the new Dassault Rafale aircraft; the Invincible class light aircraft carriers were not recognised by the American military as full aircraft carriers; Captain Fabian Malbon, commanding officer of the Invincible; the Nimitz class was heavily protected against incoming attacks; Colonel John Schmidt of the Marine Ground Force; Denis Healey, Secretary State of Defence from 1964–70 and his cancellation of new British carriers in 1966; Admiral of the Fleet Terence Lewin; Admiral Edward H.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.